Aim: Little scientific evidence is available on the costs of targeted genetic testing and surveillance programmes for the identification of hereditary colorectal cancers (HCRC). The present study is a cost analysis of an intensive surveillance programme with and without the use of genetic testing, carried out in a province of northern Italy. Additionally, cancer care using an intensive surveillance programme for gene carrier subjects was compared to cancer care in subjects not selected for genetic testing who followed unselective clinical surveillance. Methods: A model based on epidemiological factors was developed to estimate the incidence of gene carriers for Lynch Syndrome. A hypothetical cohort of 98 healthy people with a high cancer ri...
Abstract Background Due to its epidemiological relevance, several studies have been performed to ass...
Background: We estimated the cost-effectiveness of universal DNA screening for Lynch syndrome (LS) a...
OBJECTIVE: To analyze the cost effectiveness of the diagnostic program for the germline mutation in ...
BACKGROUND. It has been estimated that the prevalence of carriers of a mutated mismatch repair (MMR)...
Colorectal cancer (CRC) remains the second leading cause of cancer-related deaths worldwide. Approxi...
Lynch syndrome (LS) is an autosomal dominant condition caused by pathogenic variants in mismatch rep...
Purpose: To estimate the cost-effectiveness of genetic testing for Lynch syndrome among newly diagno...
[[abstract]]Patients with Lynch syndrome (LS) have a significantly increased risk of developing colo...
Familial colorectal cancer (CRC) accounts for 10-15% of all CRCs. In about 5% of all cases, CRC is a...
[[abstract]]Patients with Lynch syndrome (LS) have a significantly increased risk of developing colo...
Patients with Lynch syndrome (LS) have a significantly increased risk of developing colorectal cance...
Familial colorectal cancer (CRC) accounts for 10-15% of all CRCs. In about 5% of all cases, CRC is a...
Objective: Approximately 20-30% of all colorectal cancer (CRC) cases may have a familial contributio...
<p><b>Objective:</b> Approximately 20–30% of all colorectal cancer (CRC) cases may have a familial c...
Several mutations recently have been shown to be associated with hereditary nonpolyposis colon cance...
Abstract Background Due to its epidemiological relevance, several studies have been performed to ass...
Background: We estimated the cost-effectiveness of universal DNA screening for Lynch syndrome (LS) a...
OBJECTIVE: To analyze the cost effectiveness of the diagnostic program for the germline mutation in ...
BACKGROUND. It has been estimated that the prevalence of carriers of a mutated mismatch repair (MMR)...
Colorectal cancer (CRC) remains the second leading cause of cancer-related deaths worldwide. Approxi...
Lynch syndrome (LS) is an autosomal dominant condition caused by pathogenic variants in mismatch rep...
Purpose: To estimate the cost-effectiveness of genetic testing for Lynch syndrome among newly diagno...
[[abstract]]Patients with Lynch syndrome (LS) have a significantly increased risk of developing colo...
Familial colorectal cancer (CRC) accounts for 10-15% of all CRCs. In about 5% of all cases, CRC is a...
[[abstract]]Patients with Lynch syndrome (LS) have a significantly increased risk of developing colo...
Patients with Lynch syndrome (LS) have a significantly increased risk of developing colorectal cance...
Familial colorectal cancer (CRC) accounts for 10-15% of all CRCs. In about 5% of all cases, CRC is a...
Objective: Approximately 20-30% of all colorectal cancer (CRC) cases may have a familial contributio...
<p><b>Objective:</b> Approximately 20–30% of all colorectal cancer (CRC) cases may have a familial c...
Several mutations recently have been shown to be associated with hereditary nonpolyposis colon cance...
Abstract Background Due to its epidemiological relevance, several studies have been performed to ass...
Background: We estimated the cost-effectiveness of universal DNA screening for Lynch syndrome (LS) a...
OBJECTIVE: To analyze the cost effectiveness of the diagnostic program for the germline mutation in ...